Abstract

BackgroundPembrolizumab (Pb) showed significant benefit in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with untreated metastasic non-small-cell lung cancer (NSCLC) and ≥50% PD-L1 expression. The pembrolizumab-chemotherapy...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call